The present disclosure relates to compositions that are useful in the delivery of various materials. In particular, the compositions comprise a suspension wherein an internal phase material is surrounded by an external phase material. The internal phase specifically can be a hydrophilic material, and the external phase specifically can be a hydrophobic material. The materials are combined so that the internal phase is substantially encapsulated by the external phase such that release can be controlled in relation to osmotic pressure differentials. The suspension can be combined with a carrier, and various systems and products can be formed with the suspension and optional carrier, such as oral strips, spray delivery systems, smokeless tobacco products, aerosol delivery devices, cigarettes, and packaging.

A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising co-administering an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; and caffeine to the person. The components may be co-administered in a single composition, or administered in separate compositions. The mangiferin and/or norathyriol exhibit synergistic effects on brain wave activity when co-administered with caffeine.

A medication comprising a medication coated with hemp, or a composition including hemp oil, hemp seed oil, or another cannabinoid is provided.

This disclosure provides a chewing gum composition comprising an herbal extract comprising isoflavones and a gum base. The disclosure also provides methods of treating symptoms associated with menopause comprising administering to a subject in need thereof, a gum-based composition for chewing, the composition comprising an herbal extract comprising isoflavones and a gum base.

The present invention relates to a chewing gum for mucosal delivery of cannabinoids, the chewing gum includes water-soluble chewing gum ingredients and water-insoluble gum base, wherein the gum base has one or more natural resins in an amount of 10-40% by weight of the gum base, one or more elastomers in an amount of 3-30% by weight of the gum base, and one or more elastomer plasticizers in an amount of 8-50% by weight of the gum base, and wherein the chewing gum includes one or more high intensity sweeteners in an amount of 0.01 to 1% by weight of the chewing gum, and wherein the chewing gum has one or more cannabinoids.

The present invention defines a process for forming a chewable oral dosage form, such as a gum having a pleasant flavor and texture. In particular, the invention includes a process of forming an oral dosage form, comprising: a first step of hydrating a gelling agent of agar-agar and locust bean gum; a second step of mixing in components of the agar matrix; a third step of mixing in an active ingredient; a fourth step of cooking the mixture; a fifth step of flavoring; a sixth step of moulding and gelling; and a seventh step of demoulding, degreasing and drying. The oral dosage form according to the invention also comprises an agar-agar matrix combined with gums, such as locust bean gum, and/or sugar; glycerol; inulin; flavoring agents; citric acid; a coating; and water, to complete the composition, which includes active ingredients.

The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol. The menthol component can be a stabilized menthol composition comprising menthol and at least one menthol stabilizer compound including undecylenic acid methyl ester, undecylenic acid or a salt of undecylenic acid.

The disclosure provides solid products configured for oral use. The products contain a lipophilic active ingredient, a self-emulsifying delivery system (SEDS), a binder, and at least one sugar, at least one sugar alcohol, or a combination thereof. The SEDS is configured to provide droplets including the lipophilic active ingredient, the droplets have a D.sub.90 value in a range from about 10 to about 1000 nm.

Compositions configured for oral use, the compositions including at least one active ingredient selected from caffeine, taurine, GABA, theanine, tryptophan, vitamin B6, vitamin B12, vitamin C, lemon balm extract, ginseng, citicoline, sunflower lecithin, cannabinoids, cannabimimetics, terpenes, or combinations thereof, are provided. The compositions include one or more fillers, including a sugar alcohol, and optionally, a lipid or binder. The compositions may be in chewable, tablet, pastille, or meltable forms. Further provided are methods of preparing such compositions.

Disclosed herein are compositions and methods for treating, reducing or preventing oxidative stress in a subject. The compositions can be chewable confectionaries comprising a chewable base, one or more unprocessed phytochemical ingredients, and a sweetener comprising allulose. The unprocessed phytochemical ingredients can include ground plant materials selected from cinnamon, nutmeg, allspice, or combinations thereof. The chewable confectionary can exhibit a polyphenolic content of at least 100 μg gallic acid equivalents (GAE) or greater, per gram of the chewable confectionary and an antioxidant capacity of at least 3,200 μM Trolox equivalents per gram of the chewable confectionary, as determined by the oxygen radical absorbance (ORAC) assay. Kits, methods of making and using the chewable confectionary are also disclosed.